Literature DB >> 23920094

Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics.

Adrian J Brink1, Guy A Richards2, Gaia Colombo3, Fabrizio Bortolotti3, Paolo Colombo4, François Jehl5.   

Abstract

Teicoplanin and polymyxin E (colistin) are antibiotics consisting of multiple, closely related subcomponents, produced by fermentation. The principal components comprise a complex mixture of chemically related, active substances (teicoplanin A(2-1)-A(2-5) and polymyxin E(1-2), respectively), which might be required to be present in specific ratios to ensure optimal antibacterial and clinical efficacy. These subcomponents differ in their fatty acid and amino acid composition and, as such, the lipophilic and protein binding characteristics differ between components. This has therapeutic implications for critically ill patients, as the volume of distribution of the teicoplanin A2 and polymyxin E analogues at the onset of an intravenous infusion may impact on expected pharmacokinetics and influence outcome.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Colistin; Generic; ICU; Pharmacokinetics; Polymyxin E(1–2); Subcomponent; Teicoplanin A(2-1)–A(2-5)

Mesh:

Substances:

Year:  2013        PMID: 23920094     DOI: 10.1016/j.ijantimicag.2013.06.013

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  14 in total

Review 1.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

2.  Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.

Authors:  Catherine J Byrne; Jason A Roberts; Brett McWhinney; Jerome P Fennell; Philomena O'Byrne; Evelyn Deasy; Sean Egan; Ronan Desmond; Helen Enright; Sheila A Ryder; Deirdre M D'Arcy; Johnny McHugh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

3.  Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.

Authors:  Kade D Roberts; Mohammad A K Azad; Jiping Wang; Andrew S Horne; Philip E Thompson; Roger L Nation; Tony Velkov; Jian Li
Journal:  ACS Infect Dis       Date:  2015-09-04       Impact factor: 5.084

4.  Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-resistant Infections: A Systematic Review and Meta-analysis.

Authors:  Samir Samal; Shakti B Samir; Shantanu K Patra; Arun Rath; Abhilash Dash; Biswajit Nayak; Diganta Mohanty
Journal:  Indian J Crit Care Med       Date:  2021-02

5.  Determination of colistin in luminal and parietal intestinal matrices of chicken by ultra-high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Andrew Mead; Nathalie Gillard; Christelle Robert; Gilles Pierret; Jean Henrottin; Pascal Richez; Ludovic Pelligand
Journal:  J Vet Pharmacol Ther       Date:  2021-10-06       Impact factor: 1.567

Review 6.  Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives.

Authors:  Mohamed Rhouma; Francis Beaudry; William Thériault; Ann Letellier
Journal:  Front Microbiol       Date:  2016-11-11       Impact factor: 5.640

Review 7.  Antibacterial Discovery and Development: From Gene to Product and Back.

Authors:  Victor Fedorenko; Olga Genilloud; Liliya Horbal; Giorgia Letizia Marcone; Flavia Marinelli; Yossi Paitan; Eliora Z Ron
Journal:  Biomed Res Int       Date:  2015-08-03       Impact factor: 3.411

8.  Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B.

Authors:  Alejandra Gallardo-Godoy; Craig Muldoon; Bernd Becker; Alysha G Elliott; Lawrence H Lash; Johnny X Huang; Mark S Butler; Ruby Pelingon; Angela M Kavanagh; Soumya Ramu; Wanida Phetsang; Mark A T Blaskovich; Matthew A Cooper
Journal:  J Med Chem       Date:  2016-01-27       Impact factor: 7.446

9.  Consistency evaluation between matrix components ratio and microbiological potency of tylosin major components.

Authors:  Khadijeh Hamidian; Mohsen Amini; Nasrin Samadi
Journal:  Daru       Date:  2018-10-25       Impact factor: 3.117

10.  Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study.

Authors:  Jia-Yih Feng; Yi-Tzu Lee; Sheng-Wei Pan; Kuang-Yao Yang; Yuh-Min Chen; David Hung-Tsang Yen; Szu-Yuan Li; Fu-Der Wang
Journal:  Antimicrob Resist Infect Control       Date:  2021-07-30       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.